Current ADC Linker Chemistry

Jain, Nareshkumar; Smith, Sean; Ghone, Sanjeevani; Tomczuk, Bruce
November 2015
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3526
Academic Journal
The list of ADCs in the clinic continues to grow, bolstered by the success of first two marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various phases of clinical development. However, only 34 of these have published their structures. Of the 34 disclosed structures, 24 of them use a linkage to the thiol of cysteines on the monoclonal antibody. The remaining 10 candidates utilize chemistry to surface lysines of the antibody. Due to the inherent heterogeneity of conjugation to the multiple lysines or cysteines found in mAbs, significant research efforts are now being directed toward the production of discrete, homogeneous ADC products, via site-specific conjugation. These site-specific conjugations may involve genetic engineering of the mAb to introduce discrete, available cysteines or non-natural amino acids with an orthogonally-reactive functional group handle such as an aldehyde, ketone, azido, or alkynyl tag. These site-specific approaches not only increase the homogeneity of ADCs but also enable novel bio-orthogonal chemistries that utilize reactive moieties other than thiol or amine. This broadens the diversity of linkers that can be utilized which will lead to better linker design in future generations of ADCs.


Related Articles

  • Antibody-Drug Conjugates. Ritter, Amy // Pharmaceutical Technology;Jan2012, Vol. 36 Issue 1, p42 

    The article focuses on the development of antibody-drug conjugates (ADCs). It says that cytotoxins used in ADCs are more potent than the molecules used before such as doxorubicin. It states that experiences on monoclonal antibodies (mAbs) therapies were applied by developers in creating ADCs....

  • Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules. Van Arnum, Patricia // Pharmaceutical Technology;Jun2008, Vol. 32 Issue 6, p54 

    The article focuses on the importance of antibody drug conjugates (ADCs) as part of anticancer drug development in the U.S. It cites that ADCs, or monoclonal antibodies linked to a cytotoxic small molecule, provide a niche opportunity for biopharmaceutical companies and contract manufacturers....

  • Antibody-Drug Conjugates. Kulkarni, Ashutosh; Gukasyan, Hovhannes // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3451 

    No abstract available.

  • Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development. Singh, Aman; Shin, Young; Shah, Dhaval // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3508 

    Characterization and prediction of the pharmacokinetics (PK) and pharmacodynamics (PD) of Antibody-Drug Conjugates (ADCs) is challenging, since it requires simultaneous quantitative understanding about the PK-PD properties of three different molecular species i.e., the monoclonal antibody, the...

  • Linkers Having a Crucial Role in Antibody-Drug Conjugates. Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang // International Journal of Molecular Sciences;2016, Vol. 17 Issue 4, p561 

    Antibody-drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, enhancing the therapeutic parameter of the...

  • Monoclonal antibody-related drugs for cancer therapy. Guoning Li; Siping Wang; Xia Xue; Xianjun Qu; Huiping Liu // Drug Discoveries & Therapeutics;2013, Vol. 7 Issue 5, p178 

    Much progress has been made during the last few decades in the treatment of malignancies. Many types of cancer cells comprising the tumor mass carry molecular markers that are not expressed or are expressed at much lower levels in normal cells. These findings provide new leads to drug design and...

  • Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies. Chiarella, Pieranna // Recent Patents on Anti-Cancer Drug Discovery;May2011, Vol. 6 Issue 2, p258 

    Since the advent of hybridoma technology 35 years ago, research on monoclonal antibodies has developed enormously. Monoclonal antibodies of mouse origin were the first to be produced and continue to be the most popular affinity reagents for investigating the proteome of all organisms. For their...

  • Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE). Vaklavas, Christos; Forero, Andres // BioDrugs;Jun2014, Vol. 28 Issue 3, p253 

    Exploiting the highly targeted nature of monoclonal antibodies to deliver selectively to tumor cells a cytotoxic payload is an attractive concept and the successful precedents of the recent past set the stage for broader applications in the future. Antibody-drug conjugates may currently hold an...

  • Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability. Singh, Satish; Luisi, Donna; Pak, Roger // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3541 

    The convergence of advanced understanding of biology with chemistry has led to a resurgence in the development of antibody-drug conjugates (ADCs), especially with two recent product approvals. Design and development of ADCs requires the synergistic combination of the monoclonal antibody, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics